SCHEMBL770800

SCHEMBL770800

O=C(NCCC(=O)N1CCCC2CCCC=C21)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
ACHE P22303 1/20 0.44
DHODH Q02127 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CCR2 P41597 3/20 0.43
PREP P48147 2/20 0.43
FAP Q12884 1/20 0.43
PRSS1 P07477 1/20 0.42
CTSG P08311 1/20 0.42
CTRB1 P17538 1/20 0.42
CMA1 P23946 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772293 0.93 DPP4 (0.56) DPP4SMN1; SMN2KDM4EALDH1A1GAA
SCHEMBL770260 0.84 ALDH1A1 (0.46) ALDH1A1GAAL3MBTL1
SCHEMBL770222 0.84 MEN1 (0.46) DPP4ALDH1A1RAB9AL3MBTL1
SCHEMBL771368 0.84 HPGD (0.50) DPP4SMN1; SMN2ALDH1A1RAB9AL3MBTL1
SCHEMBL770429 0.84 EPHX1 (0.47) DPP4ALDH1A1
SCHEMBL771340 0.83 ALDH1A1 (0.45) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL770954 0.82 ALDH1A1 (0.42) DPP4SMN1; SMN2ALDH1A1GAA
SCHEMBL771986 0.82 MEN1 (0.52) DPP4ALDH1A1RAB9AL3MBTL1
SCHEMBL771395 0.80 OPRD1 (0.36) ALDH1A1
SCHEMBL771465 0.80 LMNA (0.41) SMN1; SMN2PREPFAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 DPP4 1092/4885SMN1; SMN2 3653/4885KDM4E 4105/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 DPP4 1125/4885SMN1; SMN2 3637/4885KDM4E 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.